Jennifer R. Verani

Research interests

Publications

• Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

  JAMA · 2022 · 10.1001/jama.2022.0470

• Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

  MMWR Morbidity and Mortality Weekly Report · 2022 · 10.15585/mmwr.mm7109e3

• Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

  MMWR Morbidity and Mortality Weekly Report · 2022 · 10.15585/mmwr.mm7148e1

• Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

  MMWR Morbidity and Mortality Weekly Report · 2022 · 10.15585/mmwr.mm7107e2

• Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

  BMJ · 2022 · https://doi.org/10.1136/bmj-2021-069761

• Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance

  JAMA · 2022 · 10.1001/jama.2022.7493

• Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

  MMWR Morbidity and Mortality Weekly Report · 2022 · 10.15585/mmwr.mm7104e3

• Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7034e3

• Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

  JAMA · 2021 · https://doi.org/10.1001/jama.2021.19499

• Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · https://doi.org/10.15585/mmwr.mm7018e1

• Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · https://doi.org/10.15585/mmwr.mm7034e2

• Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization

  Vaccine · 2021 · https://doi.org/10.1016/j.vaccine.2021.05.099

• Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2110362

• Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7038e1

• Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7020e2

• Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7044e3

• Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7032e3

• Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

  Clinical Infectious Diseases · 2021 · 10.1093/cid/ciab687

• Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021

  MMWR Morbidity and Mortality Weekly Report · 2021 · 10.15585/mmwr.mm7011e3

• Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient — Solano County, California, February 2020

  MMWR Morbidity and Mortality Weekly Report · 2020 · 10.15585/mmwr.mm6915e5

• First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA

  The Lancet · 2020 · 10.1016/s0140-6736(20)30607-3

• Factors associated with fatal cases of acute respiratory infection (ARI) among hospitalized patients in Guatemala

  BMC Public Health · 2019 · 10.1186/s12889-019-6824-z

• Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study

  The Lancet Infectious Diseases · 2019 · https://doi.org/10.1016/s1473-3099(19)30297-x

• Effects of Vaccination on Invasive Pneumococcal Disease in South Africa

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1401914

• Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

  The Lancet Respiratory Medicine · 2014 · 10.1016/s2213-2600(14)70060-8

• Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine

  Vaccine · 2012 · 10.1016/j.vaccine.2012.11.056

• Evaluation of Urine CCA Assays for Detection of Schistosoma mansoni Infection in Western Kenya

  PLoS neglected tropical diseases · 2011 · 10.1371/journal.pntd.0000951

• National Outbreak ofAcanthamoebaKeratitis Associated with Use of a Contact Lens Solution, United States

  Emerging infectious diseases · 2009 · 10.3201/eid1508.090225

Current projects

No projects listed.